AEE788 60258 with a 96% reduction in

with a 96% reduction in mean tumor volume at the final measurement compared to the start of treatment

Schöffski P

and interleukin-6 in THP-1 cells with IC50 values in the 1- to 5 μM range

reaching a maximum increase of 1

Fujimori A

AEE788 60258 with a 96% reduction inAEE 788 is an orally bioavailable multiple receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor associated endothelial cell apoptosis. Check for